HomeAI · summaries
Storia in 2 fonti
Novartis India launches Pluvicto for prostate cancer treatment
Novartis India has launched Pluvicto, the nation's first approved radioligand therapy for eligible prostate cancer patients. This precision radiotherapy precisely targets cancer cells, offering a new treatment approach for metastatic prostate cancer. The therapy will be available through select hospitals and nuclear medicine centers across India.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Novartis India launches Pluvicto for prostate cancer treatment
Novartis India has launched Pluvicto, the nation's first approved radioligand therapy for eligible prostate cancer patients. This precision radiotherapy precisely targets cancer…
- ·
thehindubusinessline.com
Novartis brings in its advanced-prostrate-cancer drug to India
Novartis launches Pluvicto, India's first approved radioligand therapy for advanced prostate cancer, enhancing precision oncology options.
